CN110036005A - 酰胺衍生物及其在药物中的应用 - Google Patents

酰胺衍生物及其在药物中的应用 Download PDF

Info

Publication number
CN110036005A
CN110036005A CN201780070415.8A CN201780070415A CN110036005A CN 110036005 A CN110036005 A CN 110036005A CN 201780070415 A CN201780070415 A CN 201780070415A CN 110036005 A CN110036005 A CN 110036005A
Authority
CN
China
Prior art keywords
base
alkyl
ring
amino
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780070415.8A
Other languages
English (en)
Other versions
CN110036005B (zh
Inventor
杨新业
潘圣强
马发城
张英勋
陈红
舒帆
熊绍辉
林继华
王晓军
张英俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CN110036005A publication Critical patent/CN110036005A/zh
Application granted granted Critical
Publication of CN110036005B publication Critical patent/CN110036005B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种酰胺衍生物及其在药物中的应用被公开。具体地，一种新型的用做ASK1活性调节剂的酰胺衍生物及其立体异构体、几何异构体、互变异构体、氮氧化物、水合物、溶剂化物、代谢产物、药学上可接受的盐或前药以及所述衍生物在制备治疗ASK1调节的疾病和/或病症药物中的用途被公开。含有所述化合物的药物组合物和使用所述化合物或药物组合物治疗ASK1调节的疾病和/或病症的方法进一步被公开。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201780070415.8A 2016-11-16 2017-11-10 酰胺衍生物及其在药物中的应用 Active CN110036005B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611008179 2016-11-16
CN2016110081790 2016-11-16
PCT/CN2017/110326 WO2018090869A1 (zh) 2016-11-16 2017-11-10 酰胺衍生物及其在药物中的应用

Publications (2)

Publication Number Publication Date
CN110036005A true CN110036005A (zh) 2019-07-19
CN110036005B CN110036005B (zh) 2022-09-27

Family

ID=62146129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780070415.8A Active CN110036005B (zh) 2016-11-16 2017-11-10 酰胺衍生物及其在药物中的应用

Country Status (2)

Country Link
CN (1) CN110036005B (zh)
WO (1) WO2018090869A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115504986A (zh) * 2017-03-03 2022-12-23 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10683279B2 (en) 2017-05-12 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218042A1 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10246439B2 (en) 2017-05-25 2019-04-02 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10450301B2 (en) 2017-05-25 2019-10-22 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10597382B2 (en) 2017-08-28 2020-03-24 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10683289B2 (en) 2018-05-02 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
AU2019262016B2 (en) 2018-05-02 2024-07-11 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN110818683B (zh) * 2018-08-10 2023-04-14 中国科学院上海药物研究所 2-吡啶取代脲结构小分子化合物及其合成和应用
CN111132984A (zh) * 2018-08-14 2020-05-08 江苏豪森药业集团有限公司 凋亡信号调节激酶1抑制剂的盐及其晶型
WO2020041417A1 (en) 2018-08-22 2020-02-27 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN111170995A (zh) * 2018-11-09 2020-05-19 山东轩竹医药科技有限公司 Ask1抑制剂及其应用
WO2020106707A1 (en) 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020198214A1 (en) 2019-03-25 2020-10-01 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
JP7406008B2 (ja) * 2020-05-12 2023-12-26 蘇州阿尓脈生物科技有限公司 Ｃｄｋ９阻害剤としての多環式アミド系誘導体、その調製方法及び用途
AU2021356641A1 (en) * 2020-10-09 2023-06-15 Buck Institute For Research On Aging Heteroaryl amide inhibitors of cd38

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101878212A (zh) * 2007-08-31 2010-11-03 默克雪兰诺有限公司 三唑并吡啶化合物及其作为ask抑制剂的用途
CN102482257A (zh) * 2009-07-13 2012-05-30 吉利德科学股份有限公司 凋亡信号调节激酶抑制剂
WO2015187499A1 (en) * 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ604831A (en) * 2010-07-02 2014-12-24 Gilead Sciences Inc Apoptosis signal-regulating kinase inhibitors
UY35212A (es) * 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
AU2014366235B2 (en) * 2013-12-20 2017-04-13 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101878212A (zh) * 2007-08-31 2010-11-03 默克雪兰诺有限公司 三唑并吡啶化合物及其作为ask抑制剂的用途
CN102482257A (zh) * 2009-07-13 2012-05-30 吉利德科学股份有限公司 凋亡信号调节激酶抑制剂
WO2015187499A1 (en) * 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115504986A (zh) * 2017-03-03 2022-12-23 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用
CN115504986B (zh) * 2017-03-03 2024-05-14 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
WO2018090869A1 (zh) 2018-05-24
CN110036005B (zh) 2022-09-27

Similar Documents

Publication Publication Date Title
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
CN109400625B (zh) 稠合双环类化合物及其在药物中的应用
WO2018157856A1 (zh) 酰胺类衍生物抑制剂及其制备方法和应用
CA2895239C (en) Compounds and methods for kinase modulation, and indications therefor
CN106854205B (zh) 流感病毒复制抑制剂及其使用方法和用途
TWI704149B (zh) 抑制瞬態電位受器ａ１離子通道
WO2023051716A1 (zh) 杂芳基衍生物parp抑制剂及其用途
JP2019536785A (ja) 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
TW201028393A (en) Kinase inhibitors and methods of their use
WO2018233553A1 (zh) 稠合双环类化合物及其在药物中的应用
HUE030773T2 (en) Nitrogen-containing heterocyclic compounds with inhibitory effect on the production of quinurenine
TWI585087B (zh) Novel tetrahydropyridine pyrimidine compounds or salts thereof
CN109988106B (zh) 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN114728962A (zh) 血浆激肽释放酶抑制剂及其用途
TW201623239A (zh) 新穎２－胺基－吡啶及２－胺基－嘧啶衍生物及其醫藥用途
WO2021164746A1 (zh) 取代芳基类化合物
CN117561244A (zh) 异吲哚啉酮类化合物及其用途
KR20220088375A (ko) 피롤아미드 화합물 및 그 용도
WO2023202623A1 (zh) Polq抑制剂化合物及其应用
CA3140017A1 (en) Polyaromatic urea derivatives and their use in the treatment of muscle diseases
WO2020224626A9 (zh) 用作激酶抑制剂的化合物及其应用
CN107793409B (zh) 二氢嘧啶类化合物及其在药物中的应用
CN118201896A (zh) PI3K-α抑制剂和其使用方法
CN111315746B (zh) 色氨酸羟化酶抑制剂和包括该抑制剂的药物组合物
WO2021197486A1 (zh) 新型螺环类化合物及其在药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 Songshan Lake Science and Technology Industrial Park, Dongguan City, Guangdong Province

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.

CP03 Change of name, title or address